

Concomitant chemoradiotherapy for treatment of non-small cell lung cancer - the Conrad study

Submission date 28/04/2009	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 29/05/2009	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 21/01/2019	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Roy Bremnes

Contact details
Oncology Department
University Hospital of North Norway
Tromsø
Norway
9038
-
roy.bremnes@unn.no

Additional identifiers

Protocol serial number
Norwegian Social Science Data Services no. 15175; UNN (PVO) no. 0147

Study information

Scientific Title
A randomised, multicentre phase III trial of combination chemotherapy +/- thoracic radiotherapy in the treatment of patients with stage III non-small cell lung cancer not eligible for radical therapy

Acronym

Conrad

Study objectives

That a combination of chemotherapy and thoracic radiation is superior to chemotherapy alone in the treatment of patients with stage III non-small cell lung cancer, non-eligible for radical therapy, with overall survival as primary endpoint.

Protocol can be found at: http://www.nlcg.no/uploads/conrad_protokoll.pdf

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. Regional Ethical Review Board approved on the 19th July 2006
2. Norwegian Social Science Data Services approved on the 7th November 2006

Study design

Open randomised multicentre phase III trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Non-small cell lung cancer

Interventions

The participants will be randomised to the following two arms:

Arm 1: Chemotherapy and thoracic radiation

Arm 2: Chemotherapy alone

Chemotherapy:

All patients will receive 4 cycles of identical regimes of chemotherapy: Oral vinorelbine tablets 60 mg/m² orally (per os) day 1 and 8 and intravenous carboplatin AUC = 5 (Calvert's formula) over one hour day 1. However, the doses will be adjusted according to age (patients age greater than 75 year will be given 75% of full dose from cure no.1) and haematological toxicity.

Schedule of radiation therapy:

Simulator planned, two opposing fields with fractionation 2.8 Gy x 15. The radiotherapy should start at the same time as or just after cycle number two. Cycle number three should be given three weeks after cycle number two.

Intervention Type

Other

Phase

Phase III

Primary outcome(s)

Overall survival, followed-up for 52 weeks.

Key secondary outcome(s)

1. Health related quality of life, assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer patients (EORTC QLQ-C30) version 3.0 and the lung cancer specific module EORTC QLQ-LC13. The questionnaires will be sent to the patients every month during the treatment period and every second month after the treatment period for a total of 10 questionnaires completed per patient.
2. Time to progression, followed-up for 52 weeks
3. In field relapse, followed-up for 52 weeks
4. Drug related adverse event frequency and severity, followed-up for 52 weeks
5. Health economics, followed-up for 52 weeks

Completion date

15/11/2013

Eligibility**Key inclusion criteria**

1. Chemo-naive patients with non-small cell lung cancer (NSCLC) locally advanced stage III, not candidates for radical radiotherapy and with no pleural effusion
2. Performance status (World Health Organization [WHO]) 0 - 2
3. Ability to understand oral and written study information
4. Both males and females, no age limit
5. S-creatinine less than 1.5 times upper reference limit, bilirubin and S-transaminase levels less than 2 times upper limits. Normal white blood-cell and platelet count.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Other

Sex

All

Key exclusion criteria

1. Other active malignancies
2. Pregnancy or breast feeding

Date of first enrolment

15/11/2006

Date of final enrolment

15/11/2013

Locations

Countries of recruitment

Norway

Study participating centre

Oncology Department

Tromsø

Norway

9038

Sponsor information

Organisation

Pierre Fabre Pharma Norden AB (Sweden)

ROR

<https://ror.org/04hdhz511>

Funder(s)

Funder type

Industry

Funder Name

Regional Health Authorities (HELSE NORD) (Norway)

Funder Name

Pierre Fabre Pharma Norden AB (Sweden)

Funder Name

Please note that the Conrad study was initiated by the Norwegian Lung Cancer Group.

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	17/09/2013	21/01/2019	Yes	No
Results article	results	01/06/2014	21/01/2019	Yes	No
Results article	results	01/05/2015	21/01/2019	Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes